Skip to main content

Table 2 The IC50 values (the drug concentrations that inhibited 50% of cell proliferation) of the compounds on HepG2 cell line

From: Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors

HepG2

20 µg/l

10 µg/l

5 µg/l

IC50 µg/l

Doxo

91.13

68.59

53.46

4.749

1

65.34

53.18

43.17

7.818

4a

82.16

60.95

15.91

8.998

4b

76.43

43.81

38.14

9.155

7a

76.04

42.56

38.17

9.348

7b

85.16

69.08

55.11

4.250

7c

67.89

41.65

35.08

10.930

7k

90.19

88.59

41.84

5.521

7l

96.62

71.84

40.25

6.117

9a

79.17

49.16

13.11

10.570

9b

73.11

33.81

8.46

13.22

9c

86.55

50.63

42.88

7.257

14a

83.75

40.75

11.39

11.27

15b

78.66

75.98

49.48

4.641

16a

72.80

66.36

54.39

3.555

16b

50.18

42.54

18.01

17.650

16c

84.32

70.57

59.17

3.427